{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=CML+%28Chronic+Myelogenous+Leukemia%29&page=5", "query": { "condition": "CML (Chronic Myelogenous Leukemia)", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 943, "total_pages": 95, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=CML+%28Chronic+Myelogenous+Leukemia%29&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=CML+%28Chronic+Myelogenous+Leukemia%29&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-17T04:21:18.295Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00003619", "title": "Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation or Isotretinoin in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Acute Lymphocytic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Leukemia", "Myelodysplastic Syndromes", "Thrombocytopenia" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "vitamin E", "type": "DIETARY_SUPPLEMENT" }, { "name": "busulfan", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "isotretinoin", "type": "DRUG" }, { "name": "topotecan hydrochloride", "type": "DRUG" }, { "name": "bone marrow ablation with stem cell support", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DIETARY_SUPPLEMENT", "DRUG", "PROCEDURE" ], "sponsor": "Drexel University College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "19 Years to 90 Years" }, "enrollment_count": null, "start_date": "1998-02", "completion_date": "2004-04", "has_results": false, "last_update_posted_date": "2013-06-26", "last_synced_at": "2026-10-17T04:21:18.295Z", "location_count": 2, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003619" }, { "nct_id": "NCT01366612", "title": "Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Myeloid Malignancies", "Acute Myelogenous Leukemia", "Chronic Myelogenous Leukemia", "Myeloproliferative Disorders", "Myelodysplastic Syndrome" ], "interventions": [ { "name": "Fludarabine and Busulfan plus/minus Total Body Irradiation (low dose)", "type": "DRUG" }, { "name": "Fludarabine and Busulfan + Low Dose Total Body Irradiation (LD TBI)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hackensack Meridian Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 53, "start_date": "2010-06-16", "completion_date": "2020-08-18", "has_results": true, "last_update_posted_date": "2026-04-03", "last_synced_at": "2026-10-17T04:21:18.295Z", "location_count": 1, "location_summary": "Hackensack, New Jersey", "locations": [ { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT01366612" }, { "nct_id": "NCT01658319", "title": "Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Nasal Type Extranodal NK/T-cell Lymphoma", "Anaplastic Large Cell Lymphoma", "Angioimmunoblastic T-cell Lymphoma", "Cutaneous B-cell Non-Hodgkin Lymphoma", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Hepatosplenic T-cell Lymphoma", "Intraocular Lymphoma", "Nodal Marginal Zone B-cell Lymphoma", "Peripheral T-cell Lymphoma", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Grade III Lymphomatoid Granulomatosis", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Adult T-cell Leukemia/Lymphoma", "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Mycosis Fungoides/Sezary Syndrome", "Recurrent Small Lymphocytic Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Multiple Myeloma", "Relapsing Chronic Myelogenous Leukemia", "Small Intestine Lymphoma", "Splenic Marginal Zone Lymphoma", "Stage III Chronic Lymphocytic Leukemia", "Testicular Lymphoma", "Waldenström Macroglobulinemia" ], "interventions": [ { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "methoxyamine", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "western blotting", "type": "GENETIC" }, { "name": "mass spectrometry", "type": "OTHER" }, { "name": "DNA analysis", "type": "GENETIC" } ], "intervention_types": [ "DRUG", "OTHER", "GENETIC" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2011-05", "completion_date": "2015-05", "has_results": false, "last_update_posted_date": "2015-08-13", "last_synced_at": "2026-10-17T04:21:18.295Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01658319" }, { "nct_id": "NCT06904066", "title": "Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Malignancy, Hematologic", "Neoplasms, Hematologic", "Neoplasms, Hematopoietic", "Blood Cancer", "Hematological Neoplasms", "Hematopoietic Malignancies", "Dysmyelopoietic Syndromes", "Hematopoetic Myelodysplasia", "Myeloid Leukemia, Acute", "Nonlymphoblastic Leukemia, Acute", "Leukemia, Lymphocytic, Acute" ], "interventions": [ { "name": "aldesleukin", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "Individual Patient TCR-Transduced PBL", "type": "BIOLOGICAL" }, { "name": "TruSight Oncology (TSO) 500", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "DEVICE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 86, "start_date": "2026-10-21", "completion_date": "2029-04-30", "has_results": false, "last_update_posted_date": "2026-10-16", "last_synced_at": "2026-10-17T04:21:18.295Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06904066" }, { "nct_id": "NCT01427881", "title": "Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Accelerated Phase Chronic Myelogenous Leukemia", "Adult Acute Lymphoblastic Leukemia in Remission", "Adult Acute Megakaryoblastic Leukemia (M7)", "Adult Acute Myeloid Leukemia in Remission", "Adult Erythroleukemia (M6a)", "Adult Nasal Type Extranodal NK/T-cell Lymphoma", "Adult Pure Erythroid Leukemia (M6b)", "Anaplastic Large Cell Lymphoma", "Angioimmunoblastic T-cell Lymphoma", "Blastic Phase Chronic Myelogenous Leukemia", "Childhood Acute Erythroleukemia (M6)", "Childhood Acute Lymphoblastic Leukemia in Remission", "Childhood Acute Megakaryocytic Leukemia (M7)", "Childhood Acute Myeloid Leukemia in Remission", "Childhood Burkitt Lymphoma", "Childhood Chronic Myelogenous Leukemia", "Childhood Diffuse Large Cell Lymphoma", "Childhood Immunoblastic Large Cell Lymphoma", "Childhood Myelodysplastic Syndromes", "Childhood Nasal Type Extranodal NK/T-cell Lymphoma", "Chronic Myelomonocytic Leukemia", "Chronic Phase Chronic Myelogenous Leukemia", "Cutaneous B-cell Non-Hodgkin Lymphoma", "de Novo Myelodysplastic Syndromes", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Hepatosplenic T-cell Lymphoma", "Intraocular Lymphoma", "Nodal Marginal Zone B-cell Lymphoma", "Noncutaneous Extranodal Lymphoma", "Peripheral T-cell Lymphoma", "Philadelphia Chromosome Negative Chronic Myelogenous Leukemia", "Post-transplant Lymphoproliferative Disorder", "Previously Treated Myelodysplastic Syndromes", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Grade III Lymphomatoid Granulomatosis", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Adult T-cell Leukemia/Lymphoma", "Recurrent Childhood Acute Lymphoblastic Leukemia", "Recurrent Childhood Acute Myeloid Leukemia", "Recurrent Childhood Anaplastic Large Cell Lymphoma", "Recurrent Childhood Grade III Lymphomatoid Granulomatosis", "Recurrent Childhood Large Cell Lymphoma", "Recurrent Childhood Lymphoblastic Lymphoma", "Recurrent Childhood Small Noncleaved Cell Lymphoma", "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Mycosis Fungoides/Sezary Syndrome", "Recurrent Small Lymphocytic Lymphoma", "Recurrent/Refractory Childhood Hodgkin Lymphoma", "Relapsing Chronic Myelogenous Leukemia", "Secondary Acute Myeloid Leukemia", "Secondary Myelodysplastic Syndromes", "Small Intestine Lymphoma", "Splenic Marginal Zone Lymphoma", "Stage III Multiple Myeloma", "Testicular Lymphoma", "Waldenström Macroglobulinemia" ], "interventions": [ { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "total-body irradiation", "type": "RADIATION" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "busulfan", "type": "DRUG" }, { "name": "allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "65 Years", "sex": "ALL", "summary": "Up to 65 Years" }, "enrollment_count": 43, "start_date": "2011-09", "completion_date": "2015-07", "has_results": true, "last_update_posted_date": "2017-05-19", "last_synced_at": "2026-10-17T04:21:18.295Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01427881" }, { "nct_id": "NCT03589729", "title": "Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia", "Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Blasts 10 Percent or More of Bone Marrow Nucleated Cells", "High Risk Myelodysplastic Syndrome", "Myeloid Sarcoma", "Myeloproliferative Neoplasm", "Philadelphia Chromosome Positive" ], "interventions": [ { "name": "Cladribine", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Dexrazoxane Hydrochloride", "type": "DRUG" }, { "name": "Gemtuzumab Ozogamicin", "type": "DRUG" }, { "name": "Idarubicin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 100, "start_date": "2018-09-19", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-10-17T04:21:18.295Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03589729" }, { "nct_id": "NCT01076270", "title": "Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Accelerated Phase Chronic Myelogenous Leukemia", "Adult Acute Lymphoblastic Leukemia in Remission", "Adult Acute Myeloid Leukemia in Remission", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Atypical Chronic Myeloid Leukemia, BCR-ABL Negative", "Blastic Phase Chronic Myelogenous Leukemia", "Chronic Phase Chronic Myelogenous Leukemia", "de Novo Myelodysplastic Syndromes", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable", "Nodal Marginal Zone B-cell Lymphoma", "Noncontiguous Stage II Adult Burkitt Lymphoma", "Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma", "Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma", "Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma", "Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma", "Noncontiguous Stage II Adult Lymphoblastic Lymphoma", "Noncontiguous Stage II Grade 1 Follicular Lymphoma", "Noncontiguous Stage II Grade 2 Follicular Lymphoma", "Noncontiguous Stage II Grade 3 Follicular Lymphoma", "Noncontiguous Stage II Mantle Cell Lymphoma", "Noncontiguous Stage II Marginal Zone Lymphoma", "Noncontiguous Stage II Small Lymphocytic Lymphoma", "Previously Treated Myelodysplastic Syndromes", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Mycosis Fungoides/Sezary Syndrome", "Recurrent Small Lymphocytic Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Hairy Cell Leukemia", "Refractory Multiple Myeloma", "Relapsing Chronic Myelogenous Leukemia", "Secondary Acute Myeloid Leukemia", "Secondary Myelodysplastic Syndromes", "Splenic Marginal Zone Lymphoma", "Stage I Multiple Myeloma", "Stage II Multiple Myeloma", "Stage III Adult Burkitt Lymphoma", "Stage III Adult Diffuse Large Cell Lymphoma", "Stage III Adult Diffuse Mixed Cell Lymphoma", "Stage III Adult Diffuse Small Cleaved Cell Lymphoma", "Stage III Adult Hodgkin Lymphoma", "Stage III Adult Immunoblastic Large Cell Lymphoma", "Stage III Adult Lymphoblastic Lymphoma", "Stage III Chronic Lymphocytic Leukemia", "Stage III Grade 1 Follicular Lymphoma", "Stage III Grade 2 Follicular Lymphoma", "Stage III Grade 3 Follicular Lymphoma", "Stage III Mantle Cell Lymphoma", "Stage III Marginal Zone Lymphoma", "Stage III Multiple Myeloma", "Stage III Small Lymphocytic Lymphoma", "Stage IV Adult Burkitt Lymphoma", "Stage IV Adult Diffuse Large Cell Lymphoma", "Stage IV Adult Diffuse Mixed Cell Lymphoma", "Stage IV Adult Diffuse Small Cleaved Cell Lymphoma", "Stage IV Adult Hodgkin Lymphoma", "Stage IV Adult Immunoblastic Large Cell Lymphoma", "Stage IV Adult Lymphoblastic Lymphoma", "Stage IV Chronic Lymphocytic Leukemia", "Stage IV Grade 1 Follicular Lymphoma", "Stage IV Grade 2 Follicular Lymphoma", "Stage IV Grade 3 Follicular Lymphoma", "Stage IV Mantle Cell Lymphoma", "Stage IV Marginal Zone Lymphoma", "Stage IV Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "plerixafor", "type": "DRUG" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 1, "start_date": "2010-06", "completion_date": "2011-02", "has_results": true, "last_update_posted_date": "2017-06-28", "last_synced_at": "2026-10-17T04:21:18.295Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01076270" }, { "nct_id": "NCT00015951", "title": "Bevacizumab, Cytarabine, and Mitoxantrone on Treating Patients With Hematologic Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "mitoxantrone hydrochloride", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "University of Maryland, Baltimore", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": null, "start_date": "2001-04", "completion_date": "2004-03", "has_results": false, "last_update_posted_date": "2019-10-17", "last_synced_at": "2026-10-17T04:21:18.295Z", "location_count": 3, "location_summary": "Atlanta, Georgia • Baltimore, Maryland", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00015951" }, { "nct_id": "NCT01251575", "title": "Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adult Acute Lymphoblastic Leukemia", "Adult Acute Myeloid Leukemia", "Adult Diffuse Large B-Cell Lymphoma", "Adult Myelodysplastic Syndrome", "Adult Non-Hodgkin Lymphoma", "Aggressive Non-Hodgkin Lymphoma", "Childhood Acute Lymphoblastic Leukemia", "Childhood Acute Myeloid Leukemia", "Childhood Diffuse Large B-Cell Lymphoma", "Childhood Myelodysplastic Syndrome", "Childhood Non-Hodgkin Lymphoma", "Chronic Lymphocytic Leukemia", "Chronic Lymphocytic Leukemia in Remission", "Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Hematopoietic and Lymphoid Cell Neoplasm", "Mantle Cell Lymphoma", "Plasma Cell Myeloma", "Prolymphocytic Leukemia", "Recurrent Chronic Lymphocytic Leukemia", "Refractory Chronic Lymphocytic Leukemia", "T-Cell Prolymphocytic Leukemia", "Waldenstrom Macroglobulinemia", "Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent Hodgkin Lymphoma" ], "interventions": [ { "name": "Allogeneic Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Fludarabine Phosphate", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Peripheral Blood Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Total-Body Irradiation", "type": "RADIATION" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER", "RADIATION" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 77, "start_date": "2010-12-01", "completion_date": "2019-02-11", "has_results": true, "last_update_posted_date": "2019-12-09", "last_synced_at": "2026-10-17T04:21:18.295Z", "location_count": 4, "location_summary": "Denver, Colorado • Salt Lake City, Utah • Seattle, Washington", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Salt Lake City", "state": "Utah" }, { "city": "Seattle", "state": "Washington" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01251575" }, { "nct_id": "NCT01218477", "title": "Dasatinib Combination Therapy With the Smoothened (SMO) Inhibitor BMS-833923 in Chronic Myeloid Leukemia (CML)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "Dasatinib", "type": "DRUG" }, { "name": "BMS-833923", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2011-01", "completion_date": "2013-04", "has_results": true, "last_update_posted_date": "2016-06-17", "last_synced_at": "2026-10-17T04:21:18.295Z", "location_count": 3, "location_summary": "San Francisco, California • Baltimore, Maryland • Houston, Texas", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01218477" } ] }